Given the data on other combination regimens based on BRAF-I, MEK-I and anti-PD-1 mAb [33, 34], we believe that the combination of vemurafenib, PEG-IFN-α-2b and cobimetinib would have difficulty finding a niche in the current treatment scenario for advanced melanoma. The gene discussed is IFNA2; the disease is melanoma.